|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alexion Pharmaceuticals Inc., of Cheshire, Conn., and Procter & Gamble Pharmaceuticals, a division of Cincinnati-based Procter & Gamble Co., completed enrollment for the pivotal Phase III efficacy trial of pexelizumab. The agent is being investigated for reducing mortality and myocardial infarction following coronary artery bypass graft (CABG) surgery. The study enrolled about 4,250 patients undergoing CABG surgery in six countries in Europe and North America.
Anadys Pharmaceuticals Inc., of San Diego, said the underwriters exercised in full their overallotment option to purchase 750,000 shares of common stock at $12.40 apiece. The exercise brings the total shares ...
Related newspaper, magazine, and journal articles:
|
|
Article: DOV Initiates Phase III Trial for Its Novel ...
PR Newswire;
September 28, 2004 ;
700+ words
...DOV Pharmaceutical, Inc ... has initiated a pivotal, Phase III, U.S. clinical ... on September 24, 2004, DOV reported the initiation of a Phase III acute pain trial in ... surgery. Dr. Warren Stern, DOV's Senior Vice President ...
|
|